CD19/CD20 CAR-engineered T cells

A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A sixmonth update.

Abstract No : 3034

Abstract Type : Poster Discussion Session

Indication : B-NHL—including DLBCL, PMBCL, CLL/SLL, MCL, TFL and FL

Intervention : CD19/CD20 CAR-engineered T cells

Technology : CAR T therapy


Between May 11, 2017, and Jan 31, 2020, 99 patients were enrolled and 87 received tandem CD19/CD20 CAR-engineered T cells across phases I/IIa. As of the cutoff date, 74 assessable patients were followed up for a median of 13.5 months (IQR 33.2 - 3.3), 62 (84%) had an objective response, and 55 (74%) had a complete response. The median progression-free survival and overall survival were all not reached. Cytokine release syndrome (CRS) occurred in 62 patients (71%), with 61% grade 1 or 2 and 10% grade 3 or more. CAR-T-cell-related encephalopathy syndrome (CRES) of grade 3 occurred in 2 patients (2%) . Three treatment-related deaths (2 in pulmonary infection and 1 in deposition of CART cells in pulmonary alveoli).


In this study, optimized tandem CD19/CD20 CAR-engineered T cells induced a potent and durable anti-tumour response with controllable CRS and CRES


Highly potent efficacy response of CAR T cell therapies in patients with heavy tumour burden

Refer to Diffuse Large B-Cell Lymphoma Market report for detailed Insights.